Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Who can take part

• Willing and able to comply with the requirements for this study and written informed consent
• Male or female age ≥ 18 years
• Diagnosis of untreated non severe aplastic anemia
• Platelet counts < 50 x 10\^9/L at least 2 times consecutively (time interval ≥ 1 week)

Who cannot take part

• Receive immunosuppressive therapy more than 4 weeks before enrollment
• Treatment with TPO-RA within 1 week before enrollment
• Previously treated with TPO-RA ≥ 4 weeks
• Previously received immunosuppressive therapy ≥ 12 weeks
• Participation in another clinical trial within 4 months before the start of this trial
• Inherited bone marrow failure syndromes
• Ferritin > 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category)
• Have an allergy to eltrombopag or any other part of this medicine
• History of radiotherapy and chemotherapy for malignant solid tumors
• Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc
• Patients with diabetic nephropathy, neuropathy, or eye disease
• Patients with poorly controlled hypertension or cardiac arrhythmia
• History of arteriovenous thrombosis within 1 year before enrollment
• Abnormal liver function: ALT or AST > 3 ULN, or TBil > 1.5 ULN after treatment
• Abnormal kidney function: Creatinine clearance < 30 ml/min, or serum creatinine (sCr) >1.5 ULN
• Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF < 45% within 4 weeks before enrollment
• Bone marrow fibrosis grade ≥ 2
• The presence of hemolytic PNH clone
• The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category)
• Pregnant or breast-feeding patients
• Patients considered to be ineligible for the study by the investigator for reasons other than the above